Evidence map›Paper›PMID 38635135›Full record

ArticleBreast cancer (Tokyo, Japan)2024

French national survey on breast cancer care: caregiver and patient views.

Christine Rousset-Jablonski, Barbara Lortal, Sophie Lantheaume, Laurent Arnould, Hélène Simon, Anne-Sophie Tuszynski, Mélanie Courtier, Soukayna Debbah, Marc Lefrançois, Sita Balbin and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Christine Rousset-JablonskiCentre Léon Bérard, Lyon, France. Christine.ROUSSET-JABLONSKI@lyon.unicancer.fr.ORCID http://orcid.org/0000-0001-7087-5687
Barbara LortalInstitut Bergonié, Bordeaux, France.
Sophie LantheaumeHôpital Privé Drôme Ardèche, Guilherand-Granges, France.
Laurent ArnouldCentre Georges-François Leclerc, Dijon, France.
Hélène SimonCentre Hospitalier Universitaire, Brest, France.
Anne-Sophie TuszynskiAssociation Cancer@Work, Anthony, France.
Mélanie CourtierAssociation Jeune Et Rose, Saint-Paul-de-Blaye, France.
Soukayna DebbahCMI, Paris, France.
Marc LefrançoisCMI, Paris, France.
Sita BalbinRoche SAS, Boulogne-Billancourt, France.
Anne-Sophie KablyRoche SAS, Boulogne-Billancourt, France.
Alain ToledanoInstitut de Radiothérapie et de Radiochirurgie Hartmann - ELSAN, Levallois-Perret, France.
Roche (France) · FRCentre de Radiothérapie Bayard · FRCentre Georges François Leclerc · FRCentre Hospitalier Régional Universitaire de Brest · FRInserm · FRInstitut Bergonié · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo improve the quality of care for patients with breast cancer, an analysis of the health-care pathway, considering feedback from both health-care practitioners (HCPs) and patients, is needed.

methodsBetween 2020 and 2022, we conducted a survey at French breast cancer centers and analyzed information from questionnaires completed by HCPs and patients. We collected information on center organization, diagnostic processes, treatment decisions and modalities, supportive care, patient advocacy groups, and work issues.

resultsTwenty-three breast cancer centers were included and questionnaires completed by 247 HCPs and 249 patients were analyzed. The centers closely followed the legal French framework for cancer treatments, which includes formal diagnostic announcements, multidisciplinary tumor boards, personalized treatment summaries, and supportive care access. HCPs and patients were satisfied with the time to diagnosis (≤ 2 weeks as evaluated by 75% of patients), time to surgery (mean 61 days), time between surgery and chemotherapy (mean 47 days), and time between surgery and radiotherapy (mean 81 days). Fertility preservation counseling for women under 40 years of age was systematically offered by 67% of the HCPs. The majority (67%) of the patients indicated that they had received a personalized treatment summary; the topics discussed included treatments (92%), tumor characteristics (84%), care pathways (79%), supportive care (52%), and breast reconstruction (33%). Among HCPs, 44% stated that reconstructive surgery was offered to all eligible patients and 57% and 45% indicated coordination between centers and primary care physicians for adverse effects management and access to supportive care should be improved, for chemotherapy and radiotherapy, respectively. Regarding patient advocacy groups, 34% of HCPs did not know whether patients had contact and only 23% of patients declared that they had such contact. For one-third of working patients, work issues were not discussed. Twenty-eight percent of patients claimed that they had faced difficulties for supportive care access. Among HCPs, 13% stated that a formal personalized survivorship treatment program was administered to almost all patients and 37% almost never introduced the program to their patients. Compliance to oral treatments was considered very good for 75-100% of patients by 62% of HCPs.

conclusionsThis study provides an updated analysis of breast cancer care pathways in France. Overall, the initial processes of diagnosis, announcement, and treatment were swift and were in agreement with the best care standards. No barriers to accessing care were identified. Based on the study findings, we proposed several strategies to improve the quality of care for patients in supportive care, coordination with primary care physicians, reconstructive surgery, and fertility preservation access.

Indexed as

Breast NeoplasmsAdultAgedCaregiversFemaleFranceHumansMiddle AgedPatient SatisfactionQuality of Health CareSurveys and QuestionnairesBreast neoplasmsCancer survivorshipFranceGood clinical practicesHealth carePatient views

Identifiers

PMID38635135
PMCPMC11194201
OpenAlexW4394918630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.